Sangeetha Ramsagar’s Post

🏆 Calling all European Life Science Innovators! 🏆 Nominations are now open for the IPO / Listing of the Year award at the European Lifestars Awards! This is your opportunity to spotlight a team that has completed a significant, impactful, or transformational IPO on any international exchange, driving the future of life sciences with their groundbreaking achievements! This prestigious award acknowledges companies that have excelled in the following areas: 💰 Amount and type of funds raised 🏃♂️ Process / speed / allocation fulfillment of securing significant new funds 🤝 Level / reputation of new investors attracted 💼 Post-finance allocation / use of proceeds 🌟 Level of value creation / value realization from the raise To qualify you must: - Be a public company - Be a company with European headquarters - Have completed an IPO (primary listing, dual-listing, or uplisting) – NOT a secondary placement or follow-on Nominate a deserving company today and help us celebrate their dedication to innovation and growth in the European life sciences landscape! Cast your nomination here: https://lnkd.in/ezjTkn6f Watch the video of last year’s winner, NewAmsterdam Pharma Corporation, and get inspired by their success. Then, cast your nominations for this year’s standout performer! #LifestarsAwards #Innovation #LifeSciences #IPO

🏆 Attention all European Life Science Innovators 🏆 Nominations are open for the Late Stage Venture Round / Series C (and beyond) Finance Raise of the Year award at the European Lifestars Awards! This is your chance to highlight a company that has made significant strides in late-stage private fundraising, shaping the future of life sciences with their groundbreaking achievements! This prestigious award recognizes companies that have excelled in the following areas: 💰 Amount of funds raised 🏃♂️ Process / speed / allocation fulfillment of securing significant new funds 🤝 Level / reputation of investors attracted 💼 Post-finance allocation / use of proceeds 🌟 Level of value creation / value realization from the raise To qualify you must - Be a fundraise by a private company - Have raised the funds in the period between 1 September 2023 and 1 August 2024 - Be a company with European headquarters Nominate a deserving company today and help us celebrate their dedication to innovation and growth in the European life sciences landscape! Cast your nomination here: https://lnkd.in/ezjTkn6f Watch the video of last year’s winner, Apollo Therapeutics, and get inspired by their success. Then, cast your nominations for this year’s standout performer! #LifestarsAwards #Innovation #LifeSciences #SeriesC #Fundraising 

🔈 Application Deadline Extended! LaunchVic ACTIVATE Cohort 2 We've extended the deadline for this round of our ACTIVATE program to give you more time to finish your application. 🌱 If you're a Victorian digital or connected health company approaching proof of concept looking to turbo-charge your investment and customer readiness, ACTIVATE is for you! Applications for this round now close at 9:00 am (AEST) on 15 April. ⌛ ACTIVATE has proven to accelerate the growth and success of Victorian digital health businesses. In Cohort 1 there were: ✔️ 14 new research projects, pilots or clinical trials started   ✔️20 new staff members hired  ✔️5 companies raised investment from angel investors, grants and an entitlement issue on the ASX, with a total raised of $20.3m  ✔️ $2.9m of revenue generated   ✔️ 25,838 patients served Plus, ACTIVATE helps you strengthen your company in advance of applying for ANDHealth’s non-dilutive investment programs. 👉Submit your application: https://loom.ly/QedkPZM Learn more: https://loom.ly/0G4j86o 📹 Thanks to LaunchVic's generous support, this program is free of charge for eligible Victorian companies.

🚀 Spotlight on Europe's Life Science Achievements! 🚀 We're thrilled to invite nominations for the Post-IPO Equity Raise of the Year award at the European Lifestars Awards! This is your chance to honor a team that has successfully completed a groundbreaking secondary placement or follow-on equity raise (not debt) on any international exchange, setting new benchmarks in the life sciences sector! This prestigious award acknowledges companies that have excelled in: 💰 Amount and type of funds raised 🏃♂️ Process / speed / allocation fulfillment of securing significant new funds 🤝 Level / reputation of new investors attracted 💼 Post-finance allocation / use of proceeds 🌟 Level of value creation / value realization from the raise To qualify you must: - Be a public company - Be a company with European headquarters - Have raised the funds in the period between 1 September 2023 and 1 August 2024 - The raise must be a secondary placement or follow-on, NOT an IPO Nominate a deserving company today and help us celebrate their dedication to innovation and growth in the European life sciences landscape! 👉 Cast your nomination here: https://lnkd.in/ezjTkn6f ✨ Get inspired by last year’s winner: Watch the video of Bicycle Therapeutics' success story, then nominate this year’s standout performer! #LifestarsAwards #LifeSciences #PostIPO

Are you building deep tech innovation in #healthtech ? Thinking of applying to #EICaccelerator? Fast track approval from is an incredible way to understand the process and discover if you're right for this program

🔬 🚨 Webinar announcement! We’ll be taking a close look at How To Secure C-Suite Sponsorship for an Alumni Program, with the invaluable help of our friends at Genentech 📅 Thursday, December 12, 2024 🕚 8am PT / 11am ET / 4pm GMT 👩💼 👨💼 We’ll have the invaluable contributions of our guests Cori Davis, Rhona O'Leary, Elizabeth Majoch and Joseph Ham-Silvestre, MBA Getting executive buy-in for an alumni program can be a formidable challenge, but one that is vital to its long-term success and effectiveness. So how do you get it on the radar and position it as an essential strategic initiative? Key Discussion Points: 📣 How to bring alumni programs to the C-suite’s attention and secure sponsorship 📣 The pivotal strategies that help gain executive backing 📣 Practical advice for organizations new to alumni programs on aligning with executive goals 📣 How to track, measure, and report outcomes to maintain ongoing executive engagement. Sign up here: https://lnkd.in/eqjiXi7K 🧠 NB Follow us EnterpriseAlumni to keep abreast of all things corporate alumni

Here are my main takeaways from the LSX World Congress this week (thank you LSX - partnering for Life Science eXecutives for providing two very informative and inspiring days!): 📊 The conference kicked off with a thought-provoking analysis of the varying returns on early vs late-stage deals, and the “string of pearl” vs “silver bullet” strategy. It was fascinating to see the data on this and the shifts we’ve seen in recent years - an early-stage string of pearls tending to generate better returns. 🔬 An excellent panel of VC leaders celebrated the current quality of early-stage science in the UK but lamented a lack of biotech companies “kicking on”, citing (1) NICE’s reluctance to provide reimbursement for new therapies, (2) the lack of executive talent in the UK vs the US, particularly clinical leadership, and (3) the lack of interest from UK pension funds to invest in growth-stage Biotech (not the case in other countries). 💲 From a funding perspective, there were lively discussions around the size and timings of Seed and Series A rounds. Whilst the overall funding environment remains challenging, we are seeing higher levels of investment in those that do manage to raise. Typical ~$5m Seed rounds are being extended to around $15m, and $100m+ Series A rounds are becoming increasingly common. Companies are also being encouraged to accept a little more dilution and raise 12-15 months before you’re on your last dollar – what used to take 6 months is now taking 12... And the key advice for those raising a Series A has not changed from last year – make sure you’re raising sufficient capital to generate clinical data pre-Series B. 🏢 An increase in Corporate Venture Capital (CVC) activity was noted, hot on the heels of Regeneron announcing a $500m commitment to their newly launched CVC fund over the next 5 years. As we see more CVCs (particularly strategics) investing alongside institutional funds, the need for alignment across the syndicate on the value inflection point and exit strategy clearly sharpens – whilst strategics are looking to create a funnel of M&A opportunities, some institutional investors traditionally favour an IPO. 👨🔬👩⚕️ Several of the panel discussions commented on talent still being a key challenge for early Biotech, particularly here in the UK. Most investors have adopted the Venture Partner or EiR construct pretty well by now, and some point to it as an effective tool for attracting executive talent into their portfolio companies. That said, the same challenges largely seem to remain, particularly here in the UK. It’s inspiring to come to work every day to try and solve one of the ongoing key problems in our wonderful industry, and I’m grateful to be able to play a small (but hopefully impactful!) role in this ever-growing ecosystem. Please feel free to reach out if you’d like to discuss any of the above topics and how Venari Partners can help your career or company with its next challenge.

"How Do You Do!": In collaboration with YVC - navigating mutual mentorship between CEOs and investors 📍 BIO-Europe® 🌍 Stockholm, Sweden 📆 November 4, 2024 🕖 17:00 – 18:00 Should mentorship be a two-way street between CEOs and biotech investors? This panel aims to uncover how CEOs and investors can significantly benefit from exchanging mentor roles and insights to drive collective success for biotech companies. Learn more about the dynamics of mutual mentorship, understand risks and rewards from engaging in reverse learning, and listen to investors and C-level professionals share real life experiences. Moderator: Philip Brainin, MD PhD MBA Panelists: Anta Gkelou Renee Aguiar-Lucander Bobby Soni Find out what else is on the agenda >> http://spr.ly/6044oqYfI #BIOEurope #Mentorship #CEOs #Investors YVC Collective

Many companies find that navigating the complexities of fundraising can be daunting, but you don't have to do it alone. 📈 2024 Highlights: The number of biotech assets in phase 3 clinical trials has increased compared to 2023. 📊 Trend Over a Decade: Over the past ten years, the number of active biotech products in phase 3 trials has increased fourfold. 🏢 Current Landscape: More than 430 companies are currently funding these trials, reflecting an annual growth rate of 13.7% since 2012 🌟 This growth in late-stage trials is attracting more investment into the biotech sector. Investors are typically more confident in funding companies with advanced clinical assets, leading to potentially higher funding rounds and partnerships Whether you're an investor on the hunt for the next big opportunity or a company in need of funding, this group is here to link you with the right people: https://lnkd.in/ey4v9x3U

🔊 🔊 🔊 At BioPharmaChem Ireland, we’re getting ready to launch BioPharmaChem Impact 24 Leaders Conference and Gala Dinner, 23 May, Cork. Why not reach out today to find out more about our sponsorship packages? We’re delighted to confirm partnerships with: ✅ GOLD SPONSOR CAMIDA Limited ✅ SILVER SPONSORS: BioPharmaChem Skillnet, IDA Ireland. 💡 👉 With a number of thought leaders already confirmed, Impact 24 will bring together diverse stakeholders from across the ecosystem to facilitate the exchange of ideas, best practices, emerging trends and more... Networking at Impact 24 will enable professionals to forge valuable connections, leading to potential partnerships and collaborations - making this the unmissable event for senior professionals from right across the ecosystem. The Gala Dinner will award the Outstanding Contribution to Sustainability in the BioPharmaChem sector. This will provide a fitting end to a truly engaging event. Connect with us today to find out more about our partnership packages... #globaltrends #ecosystem #sustainability #digitilisation #partnerships, #resilientsupplyChains #futureofwork #EUcompetitiveness #innovation #regulation